新型选择性FGFR抑制剂的结构优化和癌症治疗的最新研究进展 (2020-2025年)
Rongfei Liu1, Jinghui Qi1, Yue Liu2
1School of Pharmacy, Shandong Second Medical University, Weifang, Shandong 261053, PR China.
International immunopharmacology
|January 23, 2026
概括
蛋白氨酸激酶 (PTKs) 的异常驱动癌症. 本综述侧重于纤维细胞生长因子受体 (FGFR) 抑制剂,对于未来的癌症治疗设计和合成至关重要.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 蛋白氨酸激酶 (PTKs) 是细胞过程的关键调节者,它们的异常与癌症发展有关.
- 纤维细胞生长因子受体 (FGFRs),PTKs的一个亚家族,由于细胞内表达异常,在瘤发生中发挥着重要作用.
- 向FGFRs为各种癌症提供了一个有希望的治疗策略.
研究的目的:
- 审查和总结FGFR抑制剂领域最近的进展.
- 提供关于新型FGFR抑制剂用于癌症治疗的设计和合成的见解.
主要方法:
- 关于FGFR抑制剂的最近研究的文献综述.
- 对研究的分析,重点是FGFR抑制剂在癌症中的治疗潜力.
主要成果:
- 由于它们在瘤形成中的作用,FGFRs是癌症治疗中的关键治疗标.
- 最近的研究在开发FGFR抑制剂方面取得了重大进展.
- 这些抑制剂对未来的癌症治疗有很大的前景.
结论:
- FGFR抑制剂是开发新癌症治疗方法的重要研究领域.
- 对FGFR抑制剂的持续研究对于推进向癌症治疗至关重要.
- 本综述为未来有效的FGFR抑制剂的设计和合成提供了见解.
相关概念视频
mTOR Signaling and Cancer Progression
4.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.7K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
584
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
584
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Eukaryotic Transcription Inhibitors
10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
481
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
481
Tumor Progression
7.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.3K


